InvestorsHub Logo
Followers 1
Posts 114
Boards Moderated 0
Alias Born 12/26/2017

Re: ridinbulls post# 28058

Thursday, 08/01/2019 10:29:07 PM

Thursday, August 01, 2019 10:29:07 PM

Post# of 34624
I think the low cost of manufacture is well known. I think the revenue potential comes from this being used in both metastatic disease and as an adjuvant. A lot of patients fall into those categories. Take melanoma. Currently adjuvant therapy for stage 3 disease is anti-PD1, which has serious side effects (IRAE). Many of the anti9gens MRKR uses in pep mixes are expressed on melanoma. If Multi-TAA is better than anti-PD1 in an adjuvant setting for stage 3 disease or it can be used for earlier stage disease because of absence of toxicity, there is a large patient number that might be treatment candidates. Same case in other high, or even moderate risk patients rendered NED by surgery.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News